Blood RNA signatures for 8-week sputum tuberculosis culture sterilisation: how close are we?

<title>Extract</title> Tuberculosis (TB) treatment is not quick and fast. Currently, the World Health Organization (WHO) recommends either a 6–9 month standard TB treatment regime of isoniazid, rifampicin, pyrazinamide and ethambutol initially or the 4-month regime of rifapentine, isoniazid and pyrazinamide with moxifloxacin for drug-susceptible pulmonary TB, which is a substantial duration [1, 2]. A key burden of anti-TB treatment (ATT) involves prolonged treatment duration with significant side-effects, resulting in treatment adherence challenges [3, 4]. Numerous clinical trials have explored shorter treatment regimens of 2–4 months to enhance adherence for better disease control [5–8].